122 related articles for article (PubMed ID: 1933801)
1. A phase I clinical trial of didemnin B.
Stewart JA; Low JB; Roberts JD; Blow A
Cancer; 1991 Dec; 68(12):2550-4. PubMed ID: 1933801
[TBL] [Abstract][Full Text] [Related]
2. Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group.
Sondak VK; Kopecky KJ; Liu PY; Fletcher WS; Harvey WH; Laufman LR
Anticancer Drugs; 1994 Apr; 5(2):147-50. PubMed ID: 8049497
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of didemnin B in advanced colorectal cancer.
Jones DV; Ajani JA; Blackburn R; Daugherty K; Levin B; Patt YZ; Abbruzzese JL
Invest New Drugs; 1992 Aug; 10(3):211-3. PubMed ID: 1428730
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide.
Dorr FA; Kuhn JG; Phillips J; von Hoff DD
Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1699-706. PubMed ID: 3208814
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical study of didemnin B. A National Cancer Institute of Canada Clinical Trials Group study.
Maroun JA; Stewart D; Verma S; Eisenhauer E
Invest New Drugs; 1998; 16(1):51-6. PubMed ID: 9740544
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting.
Shin DM; Holoye PY; Murphy WK; Forman A; Papasozomenos SC; Hong WK; Raber M
Cancer Chemother Pharmacol; 1991; 29(2):145-9. PubMed ID: 1662119
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687).
Hochster H; Oratz R; Ettinger DS; Borden E
Invest New Drugs; 1998-1999; 16(3):259-63. PubMed ID: 10360606
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of didemnin B (NSC No. 325319) in advanced and recurrent cervical carcinoma: a Gynecologic Oncology Group study.
Jacobs AJ; Blessing JA; Munoz A
Gynecol Oncol; 1992 Mar; 44(3):268-70. PubMed ID: 1541440
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer.
Benvenuto JA; Newman RA; Bignami GS; Raybould TJ; Raber MN; Esparza L; Walters RS
Invest New Drugs; 1992 Jul; 10(2):113-7. PubMed ID: 1500265
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319).
Mittelman A; Chun HG; Puccio C; Coombe N; Lansen T; Ahmed T
Invest New Drugs; 1999; 17(2):179-82. PubMed ID: 10638489
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study.
Weiss RB; Peterson BL; Allen SL; Browning SM; Duggan DB; Schiffer CA
Invest New Drugs; 1994; 12(1):41-3. PubMed ID: 7960604
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study.
Williamson SK; Wolf MK; Eisenberger MA; O'Rourke M; Brannon W; Crawford ED
Invest New Drugs; 1995; 13(2):167-70. PubMed ID: 8617581
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of Didemnin B in central nervous system tumors: a Southwest Oncology Group study.
Taylor SA; Giroux DJ; Jaeckle KA; Panella TJ; Dakhil SR; Schold SC
Invest New Drugs; 1998-1999; 16(4):331-2. PubMed ID: 10426666
[TBL] [Abstract][Full Text] [Related]
14. Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent.
Chun HG; Davies B; Hoth D; Suffness M; Plowman J; Flora K; Grieshaber C; Leyland-Jones B
Invest New Drugs; 1986; 4(3):279-84. PubMed ID: 3546184
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group study.
Cain JM; Liu PY; Alberts DE; Gallion HH; Laufman L; O'Sullivan J; Weiss G; Bickers JN
Invest New Drugs; 1992 Apr; 10(1):23-4. PubMed ID: 1607250
[TBL] [Abstract][Full Text] [Related]
16. Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Muldal A; Lohmann R; Taylor M; Lopez P; Armitage G; Steward WP
Invest New Drugs; 1995; 13(3):257-60. PubMed ID: 8729956
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacological study of merbarone.
Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical trial of didemnin B in previously treated small cell lung cancer.
Shin DM; Holoye PY; Forman A; Winn R; Perez-Soler R; Dakhil S; Rosenthal J; Raber MN; Hong WK
Invest New Drugs; 1994; 12(3):243-9. PubMed ID: 7896544
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney. A Southwest Oncology Group study.
Taylor SA; Goodman P; Crawford ED; Stuckey WJ; Stephens RL; Gaynor ER
Invest New Drugs; 1992 Apr; 10(1):55-6. PubMed ID: 1607254
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a Southwest Oncology Group trial.
Weiss GR; Liu PY; O'Sullivan J; Alberts DS; Brown TD; Neefe JR; Hutchins LF
Gynecol Oncol; 1992 Jun; 45(3):303-6. PubMed ID: 1535329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
